Posted by Michael Wonder on 14 Oct 2024
UCB receives US FDA approval for 320 mg single injection device presentations of Bimzelx (bimekizumab-bkzx)
14 October 2024 - The new pre-filled syringe and pre-filled auto-injector mean that patients requiring a 320 mg dose of Bimzelx (bimekizumab-bkzx) will have single injection administration options.
UCB today announced that the US FDA has approved a 2 mL pre-filled syringe and pre-filled auto-injector, each containing 320 mg of Bimzelx (bimekizumab-bkzx).
